Journal of Prosthodontics News   June 15, 2020

Povidone‐Iodine Oral Antiseptic Rinse and Inactivation of SARS‐CoV‐2

Now online as open access in the Journal of Prosthodontics, Drs. Avinash S. Bidra, Jesse S. Pelletier, Jonna B. Westover, Samantha Frank, Seth M. Brown, and Belachew Tessema share important findings regarding the preprocedural use of Povidone‐Iodine Oral Antiseptic Rinse to inactivate SARS‐CoV‐2.

The ADA interim guidelines from April 2020 have suggested preprocedural oral rinsing with 1.5% hydrogen peroxide (commercially available in the US) or 0.2% povidone-iodine PVP-I (not commercially available in the US). Though 1.5% hydrogen peroxide is known to be antibacterial, it is chemically more unstable and there are no published studies showing the inactivation of SARS-CoV-2 using this solution at 1 minute contact period.

For this study, the authors tested virus stock against oral antiseptic solutions consisting of PVP‐I at diluted concentrations of 0.5%, 1% and 1.5%. Ethanol (70%) was tested in parallel as a positive control. PVP‐I oral antiseptics at all tested concentrations completely inactivated SARS‐CoV‐2 within 15 seconds of contact. The 70% ethanol control group was able to inactivate the virus at 30 seconds of contact.

Additional clinical research is needed, but the findings from this report can justify the use of preprocedural oral rinsing with PVP‐I (for patients and health care providers) as an adjunct to personal protective equipment, for dental and surgical specialties during the COVID‐19 pandemic.

Bidra AS, Pelletier JS, Westover JB, et al: Rapid In‐Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Using Povidone‐Iodine Oral Antiseptic Rinse. J Prosthodont 2020.


Previous Next


Back to News